The Trump administration has announced an additional $250 million in aid to the Philippines, aimed at combating tuberculosis, improving maternal health, and addressing emerging disease threats. U.S. Secretary of State Marco Rubio revealed the funding on Thursday, highlighting the initiative as part of President Donald Trump’s new foreign aid strategy.
This announcement follows the $63 million commitment made during Trump’s meeting with Philippine President Ferdinand Marcos Jr. at the White House in July. Rubio emphasized that the aid reflects the “comprehensive bond between the United States and the Philippines” and showcases a more “efficient, time-limited, and narrowly targeted” America First approach to foreign assistance.
The Philippine embassy in Washington expressed appreciation for the aid but offered no further comments. The pledge underscores Washington’s continued strategic interest in strengthening bilateral ties with Manila while shifting away from traditional aid models such as USAID.
The Trump administration has consistently sought to reduce foreign assistance, attempting to withhold billions of dollars allocated by Congress as part of its broader “America First” policy. Despite these efforts, lawmakers, led by Republicans, have set aside billions in foreign aid funding, including $11 billion that must be allocated before the September 30 deadline.
After facing lawsuits, the administration agreed to release $6.5 billion in aid but continues to fight in court to block another $4 billion. The dispute is currently under review by the U.S. Supreme Court.
The latest pledge to the Philippines highlights Trump’s direct aid strategy, which prioritizes targeted investments in key areas while scaling back traditional multilateral pipelines. As Washington redefines its foreign assistance framework, the Philippines emerges as a key partner in regional health and security cooperation.


Trump Allegedly Sought Airport, Penn Station Renaming in Exchange for Hudson River Tunnel Funding
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Japan Election 2026: Sanae Takaichi Poised for Landslide Win Despite Record Snowfall
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
New York Legalizes Medical Aid in Dying for Terminally Ill Patients
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Ohio Man Indicted for Alleged Threat Against Vice President JD Vance, Faces Additional Federal Charges
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



